Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility

Sinn, Hans‐Peter; Aulmann, Sebastian; Wirtz, Ralph M.; Schott, Sarah; Marmé, F; Varga, Zsuzsanna; Lebeau, Annette; Kreipe, Hans; Schneeweiß, Andreas

doi:10.1055/s-0033-1350831

Cited by 63 publications

(58 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinicopathological parameters alone do not inform about chemotherapy benefit because they do not adequately represent tumor's biological makeup. The need for support in treatment choice has been mirrored in the explosion of prognostic tests on the market . Two of the most widely used in Germany are uPA/PAI‐1 and EPclin, which we compared in this study.…”

Section: Discussionmentioning

confidence: 99%

EndoPredict versus uPA/PAI‐1 in breast cancer: Comparison of markers and association with clinicopathological parameters

et al. 2019

View full text Add to dashboard Cite

We retrospectively investigated concordance of EndoPredict (EPclin) with urokinase plasminogen activator and plasminogen activator inhibitor-1 (uPA/PAI-1) in 72 breast cancer patients and compared the results with grading, molecular subtype and chemotherapy recommendation. Compared to uPA/PAI-1, EPclin proved to be more conservative concerning correlation with clinicopathological parameters and was significantly associated with the recommendation of adjuvant chemotherapy. K E Y W O R D S breast cancer, prognosis, proteases | 451 JAKUBOWICZ et Al. was 57.5 years. The patients were submitted to lumpectomy or mastectomy in Augsburg at the Klinikum Augsburg, Josefinum Hospital or Diakonissen Hospital between the year 2011 and 2016. The information about chemotherapy was attained from the medical records of interdisciplinary tumor conference reports of Klinikum Augsburg or from the clinical and population-based cancer registry Augsburg. Recommendation concerning adjuvant chemotherapy was correlated with uPA/PAI-1 and EPclin results. The uPA/PAI-1 testing was performed in Klinikum Augsburg. Representative tumor tissue was obtained according to protocol as a part of routine gross pathology examination. The sample was submitted for evaluation with the use of commercial enzyme-linked immune sorbent assay (ELISA) test (Femtelle Test (EF 899), Sekisui Diagnostics, Stamford, CT). The test was conducted according to the manufacturer's protocol as described before. 9 The levels of uPA and PAI-1 were expressed in nanograms per milligram (ng/mg) of tumor protein. The cut-off-level for uPA and PAI-1 were 3 ng/mg protein and 14 ng/mg protein respectively. The specimen was preserved in 10% formaldehyde and processed into FFPE tissue, sectioned and stained with hematoxylinand-eosin (HE). For immunohistochemical analysis, paraffin sections measuring approximately 3 μm were processed in streptavidin-biotin-peroxidase and incubated with estrogen, progesterone, ki67, How to cite this article: Jakubowicz E, Martin B, Hoffmann R, et al. EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters. Breast J. 2019;25:450-454.

show abstract

Section: Discussionmentioning

confidence: 99%

EndoPredict versus uPA/PAI‐1 in breast cancer: Comparison of markers and association with clinicopathological parameters

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Biomarkers are defined as measurable cellular, biochemical or molecular alternations in biological media such as blood or tissue. Several FDA-approved multi-gene panel tests are now approved for risk prediction and diagnosis of various cancers; however, no similar biomarker tests exist for patient risk stratification of NMSC [92]. At present, there are no skin cancer screening guidelines in the United States.…”

Section: Biomarkers As a Novel Tool In Monitoring Ultraviolet Skin Damentioning

confidence: 99%

Molecular Mechanisms and Biomarkers of Skin Photocarcinogenesis

López¹,

Liu²,

Geskin³

2018

Human Skin Cancers - Pathways, Mechanisms, Targets and Treatments

View full text Add to dashboard Cite

Skin cancer is the most commonly diagnosed malignancy in the United States and worldwide. While melanoma is the deadliest form of skin cancer, non-melanoma skin cancers, which include basal cell carcinoma and squamous cell carcinoma, are responsible for significant morbidity in millions of Americans each year. While numerous attempts have been made to reduce skin cancer risk factors related to ultraviolet radiation exposure, skin cancer incidence continues to rise. Improved understanding of the molecular pathways underlying skin cancer pathogenesis has led to the investigation of new approaches to skin cancer prevention. In particular, the search for ultraviolet radiation associated biomarkers of skin cancer has become a rapidly expanding and promising area of research. Advances in genetic sequencing have facilitated the discovery of novel biomarkers, which have the potential to profoundly improve patient care. Here we will review the molecular genetics of skin cancer and analyze the existing literature of proposed biomarkers for potential use in skin cancer diagnosis and prevention.

show abstract

“…It was developed to improve discrimination between Luminal A and B subtypes. [40] The accuracy of subtype classification with MammaTyper has not yet been compared with PAM50 or IHC, and it is not currently approved for use by the FDA.…”

Section: Genomic Assaysmentioning

confidence: 99%

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons

2017

View full text Add to dashboard Cite

Molecular genomic testing provides clinicians with both prognostic (and sometimes predictive) information that can help individualize treatment and decrease the risk of over- or under-treatment. Here, we review the genomic tests that are currently available for clinical use in the management of breast cancer, discuss ongoing research related to validating and expanding their utility in different patient populations, and explain why it is important for surgeons to know how to incorporate these tools into their clinical practice in order to individualize patient treatment, reduce unnecessary morbidity, and, accordingly, improve outcomes.

show abstract

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility

Cited by 63 publications

References 86 publications

EndoPredict versus uPA/PAI‐1 in breast cancer: Comparison of markers and association with clinicopathological parameters

EndoPredict versus uPA/PAI‐1 in breast cancer: Comparison of markers and association with clinicopathological parameters

Molecular Mechanisms and Biomarkers of Skin Photocarcinogenesis

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons

Contact Info

Product

Resources

About